SUMMARY
- Ansa raised $71.5 million.
- It will increase production.
- It develops DNA technology.
Ansa Biotechnologies, an Emeryville, CA-based provider of a DNA synthesis platform, has raised $71.5 million in a Series C funding round, bringing the total amount to $211 million.
The round was led by Blue Water Life Science Advisors, with participation from Illumina Ventures, BEVC, Lightscape Partners, Agent Capital, Cerberus Ventures, Fall Line Capital, Dauntless Ventures, and Altitude Life Science Ventures.
The company will use the funds to expand its manufacturing capabilities, increase production capacity and scale operations to meet growing customer demand.
What is Ansa Biotechnologies?
Founded in 2018, Ansa Biotechnologies develops technology for producing synthetic DNA. Its proprietary enzymatic DNA synthesis platform helps scientists create long and complex DNA sequences that can be difficult to manufacture using conventional methods.
Read More:Earthly Raises $5.7M in Funding Led by Work-Bench
The company serves researchers, and organisations working in drug discovery, cell and gene therapies, vaccines and agricultural genomics.
It's platform offers sequence perfect clonal DNA of up to 50 kilobases, and sequence verified linear double stranded DNA fragments. These products help researchers turn biological designs into physical DNA for experiments and testing.
The technology is particularly relevant as AI-enabled drug discovery and biological design create demand for longer, and more complex DNA sequences. Ansa aims to help researchers manufacture these sequences with greater reliability, and predictable delivery timelines.
RECOMMENDED FOR YOU
McCann Systems Names Josh Bittner and Tom Treichel as Co-CEOs
Devin Jacobs
Apr 21, 2026
How Much Funding Has Ansa Biotechnologies Raised?
Ansa Biotechnologies has raised $71.5 million in its Series C round, bringing its total funding to $211 million.
The company has not disclosed details of its previous funding rounds in the announcement.
Who Invested in Ansa Biotechnologies’ Series C?
Blue Water Life Science Advisors led the Series C round.
Other participating investors included Illumina Ventures, BEVC, Lightscape Partners, Agent Capital, Cerberus Ventures, Fall Line Capital, Dauntless Ventures and Altitude Life Science Ventures.
The company also announced three new board appointments. Nick Naclerio, founding partner of Illumina Ventures, Brad Crutchfield, an experienced life science tools executive, and Nate Cornell, founder and chief investment officer of Blue Water Life Science Advisors, have joined the board. Crutchfield will serve as an independent director.
Why the Funding Matters
The funding will help Ansa expand it's manufacturing capacity, and serve more customers as demand for complex synthetic DNA increases.
During the past year, the company has quadrupled it's manufacturing capacity. The new investment will support further expansion, and help it meet demand from researchers working across several areas of biotechnology.
Ansa also offers an On Time Guarantee, which provides customers with a committed shipping date. If the company misses that date, the entire order is free. This gives researchers greater certainty when planning experiments, and development work.
Who founded Ansa Biotechnologies?
Ansa Biotechnologies was founded in 2018 by Dan Lin-Arlow and Sebastian Palluk. The company is headquartered in Emeryville, California.
“Researchers are coming to Ansa with increasingly ambitious designs and a straightforward expectation: deliver the DNA,” said Jason T. Gammack, CEO of Ansa Biotechnologies. “Our growth reflects the demand unlocked when scientists can reliably obtain sequences that previously held their projects back. This oversubscribed financing validates our commercial success and gives us the resources to expand our capacity, serve more customers, and drive the next generation of biological innovation.”
Market and Business Growth
Ansa has expanded its manufacturing capacity fourfold over the past year to support growing customer demand.
Its platform produces clonal DNA sequences of up to 50 kilobases and linear double stranded DNA fragments. The company serves applications in drug discovery, cell, and gene therapies, vaccines and agrigenomics.
All orders also undergo biosecurity screening. Its guaranteed shipping dates are designed to help researchers plan their work with greater predictability.
What Happens Next?
Ansa plans to expand its manufacturing capabilities, increase production and scale it's operations to serve more customers.
The company will continue developing it's enzymatic DNA synthesis platform to support researchers working with increasingly complex biological designs and AI-enabled drug discovery.
Read More:Sequel.io Raises $15M in Funding Led by Sorenson Capital








